Objectives: The diagnosis of high-grade intraductal papillary mucinous neoplasm (IPMN) is difficult to distinguish from low-grade IPMN. The aim of this study was to identify potential markers for the discrimination of high-grade and invasive (HgInv) IPMN from low-and moderate-grade dysplasia IPMN.
I
ntraductal papillary mucinous neoplasm (IPMN) is a precursor lesion of pancreatic adenocarcinoma, which has been recognized with increasing frequency during the past 3 decades. Before standardization of nomenclature by the World Health Organization in 1996 1 and Armed Forces Institute of Pathology in 1997, 2 lesions now classified as IPMN were described by a variety of names including atypical papillary hyperplasia, mucinous ductal ectasia, intraductal cystadenocarcinoma, and others. 3 Intraductal papillary mucinous neoplasm is now classified as main duct type, branch duct type, and mixed type, where neoplastic change is demonstrated in both the main and sidebranch pancreatic ducts. With increasing use of cross-sectional abdominal imaging, it has been shown that incidental abnormalities involving the pancreas are seen in 2% to 20% of patients. 4 In a review of 616 consecutive abdominal magnetic resonance imaging examinations, Lee et al 5 found incidental cystic lesions in 13.5% of patients, with less than a third being reported by radiology.
A review by Tanaka 6 identified a significantly greater risk of malignancy in those patients with involvement of the main duct. Malignant change including carcinoma in situ was reported in 57% to 92% of patients with main-duct IPMN compared with 6% to 46% in those with only branch duct involvement. Invasive adenocarcinoma was seen in 23% to 57% with main duct disease compared with only 0% to 31% with only branch duct involvement. However, certain cases of main-duct IPMN have been shown to have a lower likelihood of malignancy, with 60% of low-risk patients not progressing within 70 months of initial diagnosis. 7 As clinicians rely primarily on imaging criteria to assess the extent of ductal involvement, patients having only microscopic involvement of the main duct may easily be miscategorized, and their risk of malignancy underestimated.
Despite the many advances in current diagnostic techniques including endoscopic retrograde cholangiopancreatography with pancreatic ductoscopy, endoscopic ultrasound, aspiration cytology, computed tomography, and magnetic resonance imaging with magnetic resonance cholangiopancreatography, a definitive diagnosis or the exclusion of malignancy is often achieved only by major surgical resection. It is generally agreed that accurate differentiation of benign from malignant tumors can often not be made by the surgeon at the time of pancreatectomy but rather can be made only at histopathologic examination of the entire resected segment of pancreas. 8 Recognizing the concerns of major pancreatic resection, clinicians are regularly challenged by the need to compare the risks of surgery to watchful waiting in potentially malignant disease. The growing population of elderly patients with comorbid disease creates even a greater need for more accurate data to evaluate risks and benefits unique to a given patient.
The most robust predictor of prognosis for IPMN is the presence or absence of invasive adenocarcinoma. However, adequate tissue sampling is crucial to recognizing invasive carcinoma as it may be present in only a small part of the lesion. In addition, varying degrees of epithelial dysplasia are seen in IPMN and are generally classified as low, moderate, or high grade, with high-grade lesions considered representative of carcinoma in situ. Many lesions contain a heterogeneous pattern of dysplastic and invasive regions within the same specimen, further confounding diagnosis. This heterogeneity has hampered the utility of various imaging modalities to discern between ''benign'' and ''malignant'' lesions in situ.
The genetic progression of IPMN has not been completely defined, but it has been suggested that IPMNs disclose a progression pattern similar to the ''adenoma-carcinoma sequence'' in colorectal cancer. 9 Intraductal papillary mucinous neoplasms are known to harbor alterations of KRAS, 10 p16INK4A, 11 p53, and DPC4/SMAD4/MADH4, but the prevalence of the mutations is lower than in ductal pancreatic adenocarcinoma. An early cDNA microarray study examining about 5000 genes identified a series of up-regulated genes that were previously described in classic pancreatic carcinomas such as lipocalin 2, galectin 3, claudin 4, and cathepsin E. 13 However, the most highly upregulated genes in IPMNs corresponded to 3 members of the trefoil factor family (TFF1, TFF2, and TFF3). Hierarchical clustering implicated several genes (caveolin 1, glypican 1, growth arrestYspecific 6 protein, cysteine-rich angiogenic inducer 61) in tumor progression.
The timing and choice of appropriate surgical treatment for IPMN remain a major clinical challenge. Despite improvements in detection of the disease, no reliable markers have been identified to differentiate between different grades of disease that might help guide surgical intervention. In this study, gene expression analysis was used to compare low-and moderate-grade dysplasia (LMD) IPMN lesions to high-grade and invasive (HgInv) lesions in an effort to discover potential biomarkers to guide surgical decision making and follow-up.
MATERIALS AND METHODS

Patients and Specimens
This study used paraffin-embedded archival tissue from 14 patients who underwent resection for IPMN at William Beaumont Hospital. Table 1 describes the patient and lesion characteristics. Hematoxylin-eosin samples were reviewed by a single pathologist who identified distinct foci of low-, moderate-, and high-grade dysplasia as well as invasive adenocarcinoma arising in association with IPMN (hereafter referred to as ''invasive IPMN''). Eleven of 14 samples included multiple grades in the same specimen, and 4 samples allowed for comparison of the LMD and HgInv foci in the same patient (Table 2) .
Laser Capture Microdissection
For laser capture microdissection (LCM), 5-Km-thick sections were cut from formalin-fixed paraffin-embedded (FFPE) tissue and mounted onto polyethylene naphthalate membrane glass slides (2 sections per slide). Before deparaffinization, slides were placed into an oven set at 60-C for 25 minutes then stained and dehydrated through a series of graded ethanol and xylene steps. Within 3 hours of sectioning, the pathologist-identified areas were microdissected with both UV and IR lasers, where appropriate, using the ArcturusXT Microdissection System (Molecular Devices) onto CapSure HS LCM Caps (Molecular Devices, Sunnyvale, Calif). Four caps were used per graded region from the dissection of 1 to 4 sections representing approximately 5000 cells (1-to 2-mm 2 area) captured per cap.
RNA Isolation
RNA was isolated from the LCM tissues using the PureLink FFPE RNA Isolation Kit (Invitrogen, Carlsbad, Calif). The transfer film with the attached dissected material was separated from each CapSure HS LCM Cap and placed in deparaffinization melting buffer at 72-C for 10 minutes then treated with proteinase K at 60-C for 45 minutes. Following the manufacturer's protocol, RNA was purified using spin cartridge technology, treated with DNase, quantified (Nanodrop 8000; Thermo Scientific, Waltham, Mass), and stored at j80-C. RNA integrity was determined just before processing for microarray analysis. RNA integrity numbers ranged from 2.0 to 2.4 as determined by Bioanalyzer analysis (Agilent, Santa Clara, Calif).
Whole Transcriptome Amplification, Purification, Fragmentation, Hybridization RNA was amplified and labeled using the Whole Transcriptome (WT)YOvation FFPE System V2, WT-Ovation Exon Module, and the Encore Biotin Module (NuGEN, Inc, San Carlos, Calif ), which enables amplification and target preparation of the low-quality RNA from FFPE LCM samples. Amplifications were performed with 100 ng of total RNA input following procedures described in the WT-Ovation FFPE System user guide. Target preparation for Affymetrix Human Exon 1.0 ST Arrays (Affymetrix, Santa Clara, Calif ) was performed using 5 Kg of amplified cDNA and the Encore Biotin Module following the manufacturer's recommendations. Hybridization, washing, staining (with GeneChip Fluidics Station 450; Affymetrix), and scanning (with GeneChip Scanner 3000) were performed following the manufacturer's protocols. Array scans 
X indicates grade is present in patient sample; V, grade absent.
from this process yielded signal intensities comparable to arrays prepared from high-quality RNA from cell lines. This method has also been independently reported recently to provide optimal RNA hybridization. 14 
Gene Expression Analysis
The CEL files containing the raw intensity data from the Affymetrix GeneChip arrays were imported into Partek Genomics Suite (version 6.5, build 6.10.0312; Partek Inc, St Louis, Mo) and normalized using the robust multichip average with a guanine-cytosine content background correction, quantile normalization, log2 transformation, and median polish probeset summarization. Exons were then summarized to genes using the average of the probesets. Differentially expressed genes were identified using analysis of variance (ANOVA) (P e 0.05) with 2 factors: tumor grade and patient (random effect). Hierarchical clustering was carried out using Partek software, version 6.5 (Partek Inc). Hierarchical clustering analysis was performed using Euclidean distance as similarity measure and average linkage for the agglomerative method. Gene set enrichment analysis (GSEA) and pathway analysis were performed using Pathway Studio 7.1 (Ariadne Genomics, Rockville, Md). The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus 15 and are accessible through GEO Series accession number GSE26647.
Quantitative Real-Time Polymerase Chain Reaction
Gene expression levels were quantified using a Realplex Mastercycler (Eppendorf, Hauppauge, NY ). The following predesigned TaqMan gene-specific primers (Applied Biosystems, Grand Island, NY) were used: collagen type I>1 (COL1A1) (assay ID Hs00164004m1), fibronectin 1 (FN1) (assay ID Hs01549976m1), periostin (POSTN) (assay ID Hs00170815m1), and GAPDH (assay ID Hs99999905m1). Assay was performed on cDNA generated by the WT amplification of RNA described above. Quantitative real-time polymerase chain reaction (PCR) reaction mixture was prepared containing 1 KL cDNA (87.6 ng), 1Â TaqMan Gene Expression Master Mix (Applied Biosystems), and 1Â Gene Expression Assay (Applied Biosystems). The following thermocycling conditions were used: 50-C for 2 minutes, 95-C for 10 minutes, and 40 amplification cycles of 95-C for 15 seconds/60-C for 1 minute. The delta-delta cycle threshold (CT) method was used for analysis.
RESULTS
Identification and Isolation of IPMN Samples
Patient demographics and lesion characteristics are included in Table 1 . Intraductal papillary mucinous neoplasms were separated into various categories depending on the degree of atypia including IPMN with low-grade dysplasia, IPMN with moderate dysplasia, IPMN with high-grade dysplasia (carcinoma in situ), and IPMN with invasive carcinoma. The lesions were graded based on the highest degree of dysplasia. Intraductal papillary mucinous neoplasm with low-grade dysplasia consisted of uniform cells forming a single layer of basally oriented nuclei with abundant apical mucin (Fig. 1A) . The nuclei show mild atypia with small nuclei and inconspicuous nucleoli. Presence of mitoses is not prominent. Intraductal papillary mucinous neoplasms with moderate-grade dysplasia show some loss of nuclear polarity and evidence of nuclear stratification (Fig. 1B) . The nuclei show moderate atypia with nuclear enlargement and some nuclear pleomorphism with intact papillary architecture. Highgrade dysplasia (carcinoma in situ) shows severe architectural complexity and nuclear atypia (Fig. 1C) . There was loss of polarity with cribriforming and budding clusters of neoplastic cells into the lumen. The nuclei showed marked pleomorphism with prominent nucleoli and mitotic figures, which were located toward the luminal surface of the epithelium. Invasive carcinoma (Fig. 1D ) has breached the surrounding basement membrane and infiltrated the surrounding stroma. Laser capture microdissection was used to isolate and remove the foci of distinct histological grade. Multifocal IPMN was shown in 11 of 14 patients (Table 2) . Four patients had LMD IPMN, whereas 3 patients had HgInv IPMN. Four patients allowed for comparison of the LMD and HgInv foci in the same patient. Two patients had only low-grade IPMN, whereas another patient had only moderate-grade IPMN. In total, 28 samples were available for analysis: 10 low grade, 5 moderate grade, 6 high grade, and 7 invasive.
Gene Expression Changes in High-Grade IPMN
The 28 samples of IPMN were analyzed using the Human Exon 1.0 ST array from Affymetrix. As treatment for HgInv IPMN involves surgical resection, whereas low and moderate disease may indicate less aggressive therapy, 16 for statistical analysis LMD samples were grouped and compared with the HgInv samples. Sixty-two genes were identified as showing significant changes in expression (P e 0.05 and a 2-fold cutoff ) between HgInv and LMD IPMN (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/MPA/A128), including up-regulation of 41 genes and down-regulation of 21. Based on inspection of the raw microarray intensity data, the 62 differentially expressed genes were detectable in all IPMN samples. The most highly upregulated genes included regenerating islet-derived 3> (REG3A), FN1, and COL1A1, whereas gastrokines 1 and 2 (GKN1 and GKN2) were the mostly highly down-regulated. Hierarchical clustering using the 62 differentially expressed genes adequately delineated between the HgInv and LMD samples (Fig. 2) . The 2 LMD samples that cluster with the HgInv samples were from patients who also had HgInv foci.
For microarray validation, samples from 4 patients were used to verify the microarray results of COL1A1, FN1, and POSTN. Samples from the 4 patients included low-grade (n = 4), moderate-grade (n = 2), high-grade (n = 2), and invasive (n = 2) IPMN. Reverse transcriptase (RT)YPCR confirmed the microarray results that the 3 genes were up-regulated in HgInv IPMN compared with the LMD samples. FN1 was elevated 4.4-fold by RT-PCR and 5.1-fold by microarray. COL1A1 and POSTN demonstrated dramatically higher fold changes by RT-PCR, 128-and Ariadne Sub-Network Analysis
To better understand the biological context of the changes in HgInv IPMN, the microarray data were analyzed using Ariadne's Sub-Network Enrichment Analysis tool to identify expression subnetworks. 18, 19 Pathway Studio uses MedScan, a literature mining program that searches publicly available literature such as PubMed for relationships between entities. 20 An expression subnetwork consists of a single seed (ie, gene or functional class) and proteins associated to this seed either by regulating expression of/by the seed or by binding to the promoter of/by the seed. 21 The microarray data set is interrogated with no prior significance filtering, and enrichment of the subnetwork is determined by both the level of regulation in the network as well as the size of the network. Three of the top subnetworks altered between HgInv and LMD IPMN were built around the seeds of transforming growth factor A receptor 1 (TGF AR1), TGF-A1, and the general TGF family. The importance of TGF-A signaling is supported by the GSEA results, which had ''regulation of transforming growth factor A receptor signaling pathway'' as highly represented (Table 3 ). The 3 TGFAYassociated subnetworks were combined, and the visualized subnetwork was limited to include only those genes that were differentially expressed at ANOVA P e 0.10 and a 1.2-fold cutoff (Fig. 3) . Less stringent conditions have previously been shown to be more appropriate for pathway analysis. 22, 23 The combination of these subnetworks illustrates that TGF-A signaling networks are generally up-regulated in the more advanced HgInv IPMN compared with the LMD samples.
DISCUSSION
To optimize the clinical management of patients with intraductal papillary mucinous neoplasm, differentiation between those with premalignant and malignant change is required. Ideally, patients with progression to high-grade dysplasia would undergo resection before the development of invasive carcinoma, whereas those with low-grade or borderline change would be spared the risk of surgery. Currently, treatment of IPMN is based on various imaging techniques with no clearly defined molecular markers for progression to high-grade disease. In this study, gene expression analysis was used to discover differences in gene expression between HgInv IPMN and LMD IPMN. The longterm goal is to define a gene signature that will differentiate between HgInv and LMD IPMN and enable the clinician to better evaluate treatment options.
Formalin-fixed paraffin-embedded archival tissue from patients who had undergone resection for IPMN was reviewed by a single pathologist (M.A.F.). Despite the fact that the process of formalin fixation is known to cause fragmentation of RNA, 24 RNA from FFPE samples with similar RNA integrity to the current study has been shown to be suitable for use in microarray analysis. 25, 26 In addition, using the described methods including NuGEN WT amplification and labeling, the high-probe-density Affymetrix Exon arrays result in higher detection rates than conventional 3 ¶-based microarrays. 27 In the current study, we were able to obtain array scans with signal intensities approaching those prepared with high-quality RNA from cell lines, even though the RIN numbers indicated low-quality RNA. To best compare different grades of dysplasia, LCM was used to precisely isolate the foci of each sample representative of a given grade. This technique had several advantages. The precision of LCM allowed for analysis of tumor tissue with very little contamination from surrounding stroma. Laser capture microdissection also permitted the isolation of foci of different grades from the same tumor sample. This allowed for an intratumor comparison of tumor grade to be factored into the analysis. Although the study included only 14 patients, it involved 28 discrete foci of different grades of lesion from those 14 patients. In addition, although LCM has been used to examine the expression of single genes, 28, 29 the only IPMN study that combined LCM with global gene expression 30 did not differentiate between different histological grades of IPMN. This is the first study to use the most current microarray techniques to investigate different grades of IPMN within the same patient.
A limitation of the current study is the inability to make a comparison of branch-type versus main-duct IPMN because of an insufficient number of branch-type IPMN samples (Table 1) . In one study, Terris et al 31 showed that 30% of IPMNs are the branch type, while the remainder involved the main duct as well. In addition, IPMN in branch ducts is associated with lower-grade dysplasia and fewer invasive carcinoma. 32 In future studies, it will be important to determine the differences between main-and side-duct IPMN and include those changes into the determination of gene signatures predictive of an HgInv phenotype.
Gene expression microarray analysis identified 62 genes that were differentially expressed between HgInv and LMD IPMN. A detailed inspection of these 62 genes revealed many genes that have already been implicated in cancer. Several genes that are upregulated in HgInv IPMN are associated with pancreatic cancer and, in particular, increased invasiveness of pancreatic cancer. In pancreatic stellate cells, hypoxia was shown to increase secretion of COL1A1, POSTN, and FN1, 33 all of which were up-regulated in HgInv IPMN. Periostin is involved in cancer cell survival, epithelial-to-mesenchymal transition, invasion, and metastasis, 34 and levels were significantly increased in the serum of pancreatic cancer patients. 35 Periostin expression in pancreatic ductal adenocarcinoma is elevated versus normal pancreas and correlated to shorter survival, and, in combination with COL1A1, POSTN increased resistance to 5-fluorouracil and gemcitabine in pancreatic cancer cell lines. 36 In a study of IPMN, POSTN deposition in the stroma increased with the progression of IPMN to invasive carcinoma. 37 Another gene that is up-regulated in HgInv IPMN and has been linked to metastatic pancreatic cancer is sulfatase 1 (SULF1). Sulfatase 1 regulates the sulfation state of heparin sulfate proteoglycans, and its activity has been implicated in the progression of pancreatic cancer by increasing invasiveness despite reducing the growth activity. In primary pancreatic cancer, sulfation of heparin sulfate proteoglycans was greatly reduced in metastatic tumors compared with primary tumor implying greater SULF1 activity. 38 Other genes overexpressed in HgInv IPMN compared with LMD IPMN include veriscan and thrombospondin 2. Veriscan is involved in invasion and metastasis through roles in cell adhesion, proliferation, and angiogenesis. 39 Veriscan is overexpressed in pancreatic carcinoma compared with normal pancreas and is strongly associated with poor outcome in many cancer types. 40 Thrombospondin 2 is a glycoprotein that mediates cell-to-cell and cell-to-matrix interactions and stimulates invasion of pancreatic cancer cells. 41 In addition, several genes differentially expressed between HgInv and LMD IPMN have also been shown to be associated with gastric and esophageal cancer. Collagen type IA1 and collagen type I>2 (COL1A2) were found to be overexpressed in 40% of gastric cancers and are associated with tumor invasion and metastasis. 42 In addition, COL1A1 and collagen type XI>1 (COL11A1) were part of a set of collagen genes that could separate malignant from premalignant lesions in the stomach. 43 All 3 collagen genes are overexpressed in HgInv IPMN compared with LMD IPMN. Another gene with elevated expression in HgInv IPMN is LIM and senescent cell antigen-like domains 1 (LIMS1 also known as PINCH). LIMS1 is associated with the invasive edge of esophageal squamous cell carcinoma and may be predictive of the ability to invade and metastasize. 44 Gastrokines 1 and 2 were down-regulated in the HgInv IPMN relative to the LMD IPMN. Expression of both GKNs has been shown to be decreased in gastric cancer, and loss of either GKN1 or GKN2 was associated with a significantly worse outcome. 45 Using hierarchical clustering, the expression of these 62 differentially expressed genes could effectively discriminate between the HgInv samples from the LMD samples. Although the majority of LMD samples clustered together, 2 LMD samples clustered with the HgInv samples. These 2 samples were obtained from patients who had low-grade, high-grade, and invasive foci. Fritz et al 46 found a comparable result in an array comparative genomic hybridization study, which detected similar chromosomal aberrations in moderate-and high-grade foci from the same patient. These data suggest that, in patients with more advanced disease, areas of lower-grade dysplasia may actually be closer to progressing to high-grade or invasive carcinoma despite presenting the low-grade phenotype.
To further our understanding of the gene expression data, Pathway Studio was used to examine the underlying patterns in the complete microarray data set rather than looking at individual genes with the greatest magnitude of change. Subnetworks were constructed using the text-mining software MedScan and consist of a single gene seed connected to upstream and downstream regulators. 18, 21 Pathway Studio identifies those subnetworks that are most differentially regulated. Noteworthy were the 3 related subnetworks TGF-A1, TGF-AR1, and the broad-spectrum TGF-A family. Transforming growth factor A is expressed in both normal pancreas as well as in precursor and malignant pancreatic cancer. 47 It is a tumor suppressor in normal cells but a tumor promoter in malignant cells. Transforming growth factor A is a potent inhibitor of cellular proliferation and is involved in wound healing, immunosuppression, apoptosis, and angiogenesis. However, TGF-A signaling depends on cellular context, and disrupted TGF-A signaling has been linked to a variety of cancers including breast, colon, head and neck, and pancreatic cancers. 48 Transforming growth factor A functions in pancreatic cancer as a tumor suppressor by inhibiting cellular proliferation but also as a tumor promoter. 49 The tumor promoter activity of TGF-A is linked to altered expression of extracellular matrix proteins, stimulation of angiogenesis, and a suppression of immune response. 47 In the cancer stem cellY enriched side population of pancreatic cancer cell lines, TGF-A1 induced epithelial-to-mesenchymal transition as well increased invasiveness. 50 Modifications in TGF-A availability and signaling also play a role in pancreatic cancer. In mild-grade IPMN, A1-latencyYassociated peptide (A1-LAP), the TGF-A1 precursor, was strongly expressed in epithelial cells, whereas it was ''poorly detected'' in invasive IPMN. The invasive stroma was associated with increased A1-LAP and the latent binding protein. 51 Downstream signaling of TGF-A is mediated by various mothers against decapentaplegic homologs, including SMAD4. Mutation or deletion of SMAD4 results in loss of the tumor suppressor effect of TGF-A. 47 Inactivation of SMAD4 is associated with poorer prognosis and shorter survival in patients with adenocarcinoma of the pancreas. 52 SMAD4 deficiency does not initiate the tumor but instead promotes to accelerate the progression of pancreatic cancer. 53 Further work is required to determine the effect of TGF-A signaling in IPMN. Whereas LCM allowed for the strict analysis of IPMN tissue, the surrounding stroma has an important effect on tumor progression and development. The balance of A1-LAP, latent binding protein, and active TGF-A in the stroma may play a significant role in signaling within the tumor tissue.
The study identified genes involved in pancreatic disease and new genes that have not been known to be involved previously. The samples in this study were obtained from patients undergoing pancreatic resection. In a clinical setting, sampling of IPMN for analysis would be difficult; therefore, biomarkers that could be measured with less invasive procedures would be crucial. Studies of pancreatic fluid have used high TGF-> levels to differentiate IPMN from other pancreatic disorders, 54 whereas elevated mucin 1 levels were useful in detecting malignant disease in IPMN patients. 55 Of interest in the current analysis were 24 genes that encode proteins identified as secreted by UniProt using the DAVID Functional Annotation Tool (see Table 2 , Supplemental Digital Content 2, http://links.lww.com/MPA/A129). The products of these genes will be studied in a prospective series of patients where serum and/or pancreatic fluid are available. This study provides a detailed exploration of gene expression in the progression of IPMN and uncovers new directions for further investigation.
